Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA4 | P22748 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31302273 | 1.00 | CA1 (0.49) | CA1CA2CA4CA9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31302250 | 0.89 | CA1 (0.50) | CA1CA2CA4CA9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6936614 | 0.89 | CA1 (0.50) | CA1CA2CA4CA9ALDH1A1 | |
| SCHEMBL18577267 | 0.78 | CHIT1 (0.43) | CA1CA2CA4CA9L3MBTL1 | |
| SCHEMBL18577265 | 0.78 | CHIT1 (0.43) | CA1CA2CA4CA9L3MBTL1 | |
| SCHEMBL19049072 | 0.72 | CA1 (0.60) | CA1CA2CA4CA9POLB | |
| SCHEMBL18997562 | 0.72 | CA1 (0.57) | CA1CA2CA4CA9ALDH1A1 | |
| SCHEMBL4749948 | 0.72 | CA1 (0.62) | CA1CA2CA4CA9KMT2A | |
| SCHEMBL5719329 | 0.72 | CA1 (0.62) | CA1CA2CA4CA9KMT2A | |
| SCHEMBL3495230 | 0.72 | CA1 (0.62) | CA1CA2CA4CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2023043836-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368127-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | CA1 2294/4885CA2 2149/4885CA4 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.